← Back to Search

Monoclonal Antibodies

Bamlanivimab for Coronavirus (B-EPIC Trial)

Phase 4
Waitlist Available
Research Sponsored by Fraser Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post-treatment
Awards & highlights

B-EPIC Trial Summary

This study is evaluating whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.

Eligible Conditions
  • Coronavirus

B-EPIC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Any incidence of admission to hospital for >24 hours in the 28 days following first positive test for SARS-CoV2.
Secondary outcome measures
Any incidence of admission to hospital for >24 hours following first positive test for SARS-CoV2.
Health-related quality of life assessment.
Hospitalization by age and comorbidities.
+5 more

Side effects data

From 2021 Phase 3 trial • 1180 Patients • NCT04497987
2%
Urinary tract infection
1%
Atrial fibrillation
1%
Palpitations
1%
Dizziness
1%
Sepsis
1%
Vertigo
1%
Gastrooesophageal reflux disease
1%
Tooth abscess
1%
Tooth infection
1%
Contusion
1%
Fall
1%
Blood pressure increased
1%
Arthralgia
1%
Back pain
1%
Pain in extremity
1%
Depression
1%
Rash
1%
Urticaria
1%
Constipation
1%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
4200mg Bamlanivimab

B-EPIC Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Administration of Bamlanivimab
Group II: ControlActive Control1 Intervention
Standard of care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bamlanivimab
FDA approved

Find a Location

Who is running the clinical trial?

University of British ColumbiaOTHER
1,410 Previous Clinical Trials
1,765,995 Total Patients Enrolled
Clinical Trials BC (part of the BC Academic Health Science Network)UNKNOWN
Ministry of Health, British ColumbiaOTHER_GOV
9 Previous Clinical Trials
14,541 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
Gregory Haljan, MD 2021. "A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04796402.
~141 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top